Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Market Cap: US$2.0b

Mirum Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:MIRM Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Sep 24BuyUS$4,301Frazier Life Sciences Management, LPCompany115US$37.40
06 Sep 24BuyUS$9,563Frazier Life Sciences Management, LPCompany230US$41.58
27 Mar 24BuyUS$49,600Eric BjerkholtIndividual2,000US$24.80
25 Mar 24SellUS$111,017Peter RadovichIndividual4,303US$25.80
18 Mar 24BuyUS$51,600Eric BjerkholtIndividual2,000US$25.80
02 Feb 24SellUS$157,491Christopher PeetzIndividual6,013US$26.19
02 Feb 24SellUS$31,797Pamela VigIndividual1,214US$26.19
02 Feb 24SellUS$46,883Peter RadovichIndividual1,790US$26.19
02 Feb 24SellUS$22,184Lara LongpreIndividual847US$26.19
08 Jan 24SellUS$146,033Christopher PeetzIndividual5,209US$28.03
08 Jan 24SellUS$39,472Pamela VigIndividual1,408US$28.03
08 Jan 24SellUS$39,473Peter RadovichIndividual1,408US$28.03
08 Jan 24SellUS$28,568Lara LongpreIndividual1,019US$28.04

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MIRM?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders832,9041.5%
Hedge Funds3,075,9075.53%
VC/PE Firms6,570,39211.8%
Institutions45,120,84481.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.

Top Shareholders

Top 25 shareholders own 86.47% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.7%
Frazier Life Sciences Management, LP
6,570,392US$272.7m1.15%10.58%
9.33%
Janus Henderson Group plc
4,480,284US$186.0m-10.2%0.07%
7.18%
Eventide Asset Management, LLC
3,445,363US$143.0m-4.69%2.52%
7.02%
BlackRock, Inc.
3,368,157US$139.8m4.02%no data
6.41%
BVF Partners L.P.
3,075,907US$127.7m-29.6%4.09%
5.2%
The Vanguard Group, Inc.
2,496,112US$103.6m2.02%no data
3.74%
State Street Global Advisors, Inc.
1,793,728US$74.5m19.9%no data
3.29%
Rock Springs Capital Management LP
1,580,488US$65.6m-10.8%2.26%
3.12%
Novo Holdings A/S
1,500,000US$62.3m0%0.04%
2.9%
Citadel Advisors LLC
1,391,409US$57.8m-12.3%0.06%
2.68%
Tang Capital Management, LLC
1,287,107US$53.4m0%3.97%
2.67%
T. Rowe Price Group, Inc.
1,284,106US$53.3m7.08%no data
1.95%
Geode Capital Management, LLC
936,197US$38.9m3.2%no data
1.87%
Pictet Asset Management Limited
895,690US$37.2m2.35%0.03%
1.85%
ClearBridge Investments, LLC
889,100US$36.9m27%0.03%
1.65%
Medical Strategy GmbH, Asset Management Arm
794,125US$33.0m0%2.02%
1.54%
Lord, Abbett & Co. LLC
741,368US$30.8m15,200%0.09%
1.52%
Avidity Partners Management, L.P.
731,104US$30.3m0%1.75%
1.41%
Polar Capital Holdings Plc
675,000US$28.0m-8.91%0.1%
1.35%
First Turn Management, LLC
647,611US$26.9m-7.93%4.64%
1.28%
Norges Bank Investment Management
614,905US$25.5m0%no data
1.25%
Goldman Sachs Group, Investment Banking and Securities Investments
598,136US$24.8m-17.7%0.01%
1.23%
Franklin Resources, Inc.
589,967US$24.5m-37.2%0.01%
1.21%
Morgan Stanley, Investment Banking and Brokerage Investments
581,189US$24.1m9.86%no data
1.13%
Boone Capital Management LLC
543,843US$22.6m3.85%6.28%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mirum Pharmaceuticals, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc